A Novel Signature Constructed by RNA-Binding Protein Coding Genes to Improve Overall Survival Prediction of Glioma Patients
Open Access
- 28 January 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
Abstract
RNA binding proteins (RBPs) have been reported to be involved in cancer malignancy but related functions in glioma have been less studied. Herein, we screened 14 prognostic RBP genes and constructed a risk signature to predict the prognosis of glioma patients. Univariate Cox regression was used to identify overall survival (OS)-related RBP genes. Prognostic RBP genes were screened and used to establish the RBP-signature using the least absolute shrinkage and selection operator (Lasso) method in The Cancer Genome Atlas (TCGA) cohort. The 14 RBP genes signature showed robust and stable prognostic value in the TCGA training (n = 562) cohort and in three independent validation cohorts (Chinese Glioma Genome Atlas [CGGA]seq1, CGGAseq2, and GSE16011 datasets comprising 303, 619, and 250 glioma patients, respectively). Risk scores were calculated for each patient and high-risk gliomas were defined by the median risk score in each cohort. Survival analysis in subgroups of glioma patients showed that the RBP-signature retained its prognostic value in low-grade gliomas (LGGs) and glioblastomas (GBM)s. Univariate and multivariate Cox regression analysis in each dataset and the meta cohort revealed that the RBP-signature stratification could efficiently recognize high-risk gliomas [Hazard Ratio (HR):3.662, 95% confidence interval (CI): 3.187–4.208, p < 0.001] and was an independent prognostic factor for OS (HR:1.594, 95% CI: 1.244–2.043, p < 0.001). Biological process and KEGG pathway analysis revealed the RBP gene signature was associated with immune cell activation, the p53 signaling pathway, and the PI3K-Akt signaling pathway and so on. Moreover, a nomogram model was constructed for clinical application of the RBP-signature, which showed stable predictive ability. In summary, the RBP-signature could be a robust indicator for prognostic evaluation and identifying high-risk glioma patients.Keywords
Funding Information
- National Natural Science Foundation of China (81660420, 81860448, 81960456)
- Natural Science Foundation of Jiangxi Province (20171ACB20035, 20192BAB205077)
This publication has 28 references indexed in Scilit:
- Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathwaysMolecular Oncology, 2019
- The RNA Binding Protein IMP2 Preserves Glioblastoma Stem Cells by Preventing let-7 Target Gene SilencingCell Reports, 2016
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade GliomasNew England Journal of Medicine, 2015
- A census of human RNA-binding proteinsNature Reviews Genetics, 2014
- Subcellular Distribution of the Human Putative Nucleolar GTPase GNL1 is Regulated by a Novel Arginine/Lysine-Rich Domain and a GTP Binding Domain in a Cell Cycle-Dependent MannerJournal of Molecular Biology, 2012
- Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than HistologyCancer Research, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- RDM1, a Novel RNA Recognition Motif (RRM)-containing Protein Involved in the Cell Response to Cisplatin in VertebratesJournal of Biological Chemistry, 2005
- Crystal structure of human ISG20, an interferon‐induced antiviral ribonucleaseFEBS Letters, 2004
- affy—analysis of Affymetrix GeneChip data at the probe levelBioinformatics, 2004